Trial Profile
PHASE 1B, OPEN LABEL STUDY TO CHARACTERIZE THE DISTRIBUTION OF A SINGLE INTRAVENOUS DOSE OF [124I]-IODOBENZOYL (IB)-PF-06687234 WITH CONCURRENT ADMINISTRATION OF NON-RADIOLABELED PF-06687234 AS ASSESSED WITH POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET-CT) IMAGING IN MODERATE TO SEVERE ULCERATIVE AND CROHN'S COLITIS SUBJECTS
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2020
Price :
$35
*
At a glance
- Drugs F8 IL10 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Oct 2020 Status changed from suspended to discontinued due to not being able to recruit subjects.
- 16 Jun 2020 Planned End Date changed from 18 Mar 2021 to 1 Feb 2022.
- 16 Jun 2020 Planned primary completion date changed from 18 Mar 2021 to 1 Feb 2022.